Showing 1371-1380 of 1610 results for "".
- EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for Yutiq Now in Effecthttps://modernod.com/news/eyepoint-pharmaceuticals-announces-permanent-and-specific-j-code-for-yutiq-now-in-effect/2476934/EyePoint Pharmaceuticals announced that the company’s permanent and specific J-Code for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the
- Ocular Therapeutix Announces Early Assignment of Permanent and Specific J-Code for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-early-assignment-of-permanent-and-specific-j-code-for-dextenza/2476773/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dextenza (dexamethasone ophthalmic insert) 0.4 mg, which is approved for the
- EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code for Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-early-assignment-of-permanent-and-specific-j-code-for-yutiq/2476769/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code, J7314, through the Healthcare Common Procedure Coding System (HCPCS) for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micr
- Omeros’ Omidria Receives Product-Specific J-Code from CMShttps://modernod.com/news/omeros-omidria-receives-product-specific-j-code-from-cms/2476766/Omeros announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3%. Omidria is
- Permanent J Code Issued for Avedro’s Photrexa Drug Formulationshttps://modernod.com/news/permanent-j-code-issued-for-avedros-photrexa-drug-formulations/2479654/Avedro announced that the Centers for Medicare and Medicaid Services (CMS) issued a product-specific J code, J2787, for Photrexa Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa (riboflavin 5’-phosphate ophthalmic solution). These Photrexa formulations are the onl
- EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for Dexycu by CMShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-assignment-of-permanent-j-code-for-dexycu-by-the-center-for-medicare-and-medicaid-services-cms/2479679/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dexycu (dexamethasone intraocular suspension) 9%. Dexycu is the first and only
- Neurolens Appoints Thomas J. Chirillo as Chief Commercial Officerhttps://modernod.com/news/neurolens-appoints-thomas-j-chirillo-as-chief-commercial-officer/2479876/Neurolens announced the appointment of Thomas J. Chirillo as Chief Commercial Officer. An accomplished senior healthcare executive with deep experience in the eye care space, Mr. Chirillo brings almost 4 decades of sales and marketing experience to neurolens. “We’re thrilled to have someon
- ScienceBased Health Welcomes New Members to Its Optometry Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-welcomes-new-members-to-its-optometry-clinical-advisory-panel/2481787/ScienceBased Health (SBH) announced the addition of Jaclyn Garlich, OD, FAAO; Jacob Lang, OD, FAAO, Dipl ABO; and Mark Schaeffer, OD to its Optometry Clinical Advisory Panel. ScienceBased Health develops and markets e
- Harrow Announces Permanent, Product-Specific J-Code for Iheezo for Ocular Surface Anesthesiahttps://modernod.com/news/harrow-announces-permanent-product-specific-j-code-j2403-for-iheezo-for-ocular-surface-anesthesia/2481378/Harrow announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent, product-specific J-code for Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Under the Healthcare Common Procedure Coding System (HCPCS), the Iheezo J‑co
- Ocular Therapeutix Announces Permanent J-Code for Dextenza Effective October 1, 2019https://modernod.com/news/ocular-therapeutix-announces-permanent-j-code-for-dextenza-effective-october-1-2019/2476930/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code for Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use. Under the Healthcare Common Procedure Coding System (HCPCS), the J-code (J1096) will